Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

FDA approves ocular antiinflammatory agent

March 11, 1998

Preliminary results reported from phase II trials of Vitrase

March 6, 1998

Improved vision in AMD patients in phase I/II using PhotoPoint technology

Feb. 25, 1998

Allergan's new antiglaucoma agents

Feb. 20, 1998

Genetic basis for RP described

Feb. 5, 1998

FDA issues approvable letter for BioLon

Feb. 4, 1998

Novo Nordisk discloses peripheral muscarinic cholinergic agonists

Jan. 13, 1998

NIH contemplates licensing ophthalmic technology to GenVec

Jan. 7, 1998

Alcon discloses new antiglaucoma agents in patent literature

Jan. 2, 1998

Medarex's secondary cataract product enters phase III

Dec. 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...